Case Comprehensive Cancer Center

Case Western Reserve University

Cleveland, OH

Sorting 5 by

Accepting patients

Azacitidine and Decitabine

Proof-Of-Concept Study of Metabolically Optimized, Non-Cytotoxic 5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies
Learn more
  • Hypomethylating Agents (HMA)
  • Phase 1

Not yet accepting

Donor Lymphocyte Infusion Post-Transplant

Preemptive Infusion of Donor Lymphocytes Depleted of TCR (Alpha-beta) + T Cells and CD19+ B Cells Following Allogeneic Stem Cell Transplantation
Learn more
  • Donor Lymphocyte Infusion (DLI)
  • Phase 1
All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trials

Accepting patients

Connect® Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry
Learn more
  • Observational Trial

Accepting patients

Ivosidenib (AG120)

Phase Ib/II Investigator Initiated Study of the IDH1-Mutant Inhibitor Ivosidenib (AG120) With the BCL2 Inhibitor Venetoclax +/- Azacitidine in IDH1-Mutated Hematologic Malignancies
Learn more
  • BCL-2 Inhibitor
  • Hypomethylating Agents (HMA)
  • IDH1 Inhibitor
  • Phase 1/2
  • Has results

Accepting patients

NK Cells Plus Vactosertib

A Phase Ib Study to Evaluate Safety and Persistence of ex Vivo Expanded Universal Donor NK Cells in Combination With IL-2 and TGFbeta Receptor I Inhibitor Vactosertib in Patients With Locally Advanced/Metastatic Colorectal Cancer and Relapsed/Refractory Hematologic Malignancies
Learn more
  • Kinase Inhibitor
  • Natural Killer Cells (Allogeneic)
  • Phase 1